{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:11Z","timestamp":1793502911006,"version":"4.5.0"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.1001\/jamacardio.2018.4178","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T11:39:46Z","timestamp":1544614786000},"page":"59","source":"Crossref","is-referenced-by-count":62,"title":["Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab"],"prefix":"10.1001","volume":"4","author":[{"given":"Arman","family":"Qamar","sequence":"first","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Keech","sequence":"additional","affiliation":[{"name":"Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia F.","family":"Kuder","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Kurtz","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Wasserman","sequence":"additional","affiliation":[{"name":"Amgen, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Sever","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terje R.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Oslo University Hospital, Ullev\u00e5l and Medical Faculty, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Deputy Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"hbr180028r1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"hbr180028r2","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","article-title":"Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents.","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"hbr180028r3","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.atherosclerosis.2015.03.004","article-title":"Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.","volume":"240","author":"Descamps","year":"2015","journal-title":"Atherosclerosis"},{"issue":"18","key":"hbr180028r4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"hbr180028r5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","article-title":"Rationale and design of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk trial.","volume":"173","author":"Sabatine","year":"2016","journal-title":"Am Heart J"},{"issue":"16","key":"hbr180028r6","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab.","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"hbr180028r7","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"hbr180028r8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.amjcard.2005.09.134","article-title":"Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) study.","volume":"97","author":"Simon","year":"2006","journal-title":"Am J Cardiol"},{"issue":"23","key":"hbr180028r9","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","article-title":"Pharmacogenetic study of statin therapy and cholesterol reduction.","volume":"291","author":"Chasman","year":"2004","journal-title":"JAMA"},{"issue":"9","key":"hbr180028r10","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1161\/ATVBAHA.109.188474","article-title":"Identification of genetic variants associated with response to statin therapy.","volume":"29","author":"Mega","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"hbr180028r11","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.amjcard.2013.01.297","article-title":"A pilot study identifying statin nonadherence with visit-to-visit variability of low-density lipoprotein cholesterol.","volume":"111","author":"Mann","year":"2013","journal-title":"Am J Cardiol"},{"issue":"4","key":"hbr180028r12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00228-015-1994-9","article-title":"Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies.","volume":"72","author":"Trompet","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"hbr180028r13","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamacardio.2017.0747","article-title":"Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study.","volume":"2","author":"Koren","year":"2017","journal-title":"JAMA Cardiol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2716723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T11:19:06Z","timestamp":1547637546000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2018.4178"}},"subtitle":["An Analysis of FOURIER Trial Data"],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2018.4178","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,1]]}}}